By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


Key Statistics

Ownership: Public

Web Site: Bristol-Myers Squibb
Symbol: BMY



PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead (Seattle, WA) 

Company News
Bristol-Myers Squibb (BMY) To Take Part In Leerink Swann Global Healthcare Conference 2/3/2016 11:50:06 AM
Bonnie J. Addario Lung Cancer Foundation Honors Bristol-Myers Squibb (BMY) For Improving And Advancing Breakthrough Treatments For Lung Cancer 2/3/2016 9:38:27 AM
Bristol-Myers Squibb Foundation Awards Eight Grants Totaling Nearly $11.5 Million To Make Lung And Skin Cancer Screening, Care More Accessible In High-Risk U.S. Communities 2/1/2016 10:12:57 AM
Bay Area's Portola (PTLA) Wrangles Andexanet Alfa Deal Worth $120 Million from Bristol-Myers Squibb (BMY), Pfizer (PFE) 2/1/2016 5:42:47 AM
Bristol-Myers Squibb (BMY) And AbbVie (ABBV) Receive Positive CHMP Opinion Forinvestigational Antibody, Empliciti (Elotuzumab), For The Treatment Of Multiple Myeloma In Patients Who Have Received At Least One Prior Therapy 1/29/2016 9:17:12 AM
Bristol-Myers Squibb (BMY) Release: CheckMate -141, A Pivotal Phase 3 Opdivo (Nivolumab) Head And Neck Cancer Trial, Stopped Early 1/28/2016 10:21:18 AM
Bristol-Myers Squibb (BMY) Reports Fourth Quarter And Full Year 2015 Financial Results 1/28/2016 9:57:21 AM
Bristol-Myers Squibb (BMY)’s Opdivo (Nivolumab) + Yervoy (Ipilimumab) Regimen Receives Expanded FDA Approval In Unresectable Or Metastatic Melanoma Across BRAF Status1 1/25/2016 11:25:54 AM
Bristol-Myers Squibb (BMY), Dual Therapeutics Launch $255 Million+ Cancer Pact 1/11/2016 6:20:52 AM
Bristol-Myers Squibb (BMY) To Present At J.P. Morgan Healthcare Conference 1/5/2016 11:39:55 AM